South Korea
· Delayed Price · Currency is KRW Samsung Biologics Statistics
Total Valuation
KRX:207940 has a market cap or net worth of KRW 75.96 trillion. The enterprise value is 75.23 trillion.
| Market Cap | 75.96T |
| Enterprise Value | 75.23T |
Important Dates
The next estimated earnings date is Tuesday, January 20, 2026.
| Earnings Date | Jan 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:207940 has 46.29 million shares outstanding.
| Current Share Class | 46.29M |
| Shares Outstanding | 46.29M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 14.12% |
| Float | 11.83M |
Valuation Ratios
The trailing PE ratio is 47.60 and the forward PE ratio is 40.07. KRX:207940's PEG ratio is 1.38.
| PE Ratio | 47.60 |
| Forward PE | 40.07 |
| PS Ratio | 13.80 |
| PB Ratio | 6.24 |
| P/TBV Ratio | 8.03 |
| P/FCF Ratio | 95.97 |
| P/OCF Ratio | 34.29 |
| PEG Ratio | 1.38 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.80, with an EV/FCF ratio of 95.03.
| EV / Earnings | 47.14 |
| EV / Sales | 13.67 |
| EV / EBITDA | 27.80 |
| EV / EBIT | 36.97 |
| EV / FCF | 95.03 |
Financial Position
The company has a current ratio of 1.69, with a Debt / Equity ratio of 0.10.
| Current Ratio | 1.69 |
| Quick Ratio | 0.52 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.45 |
| Debt / FCF | 1.54 |
| Interest Coverage | 38.08 |
Financial Efficiency
Return on equity (ROE) is 14.02% and return on invested capital (ROIC) is 10.10%.
| Return on Equity (ROE) | 14.02% |
| Return on Assets (ROA) | 7.34% |
| Return on Invested Capital (ROIC) | 10.10% |
| Return on Capital Employed (ROCE) | 13.85% |
| Revenue Per Employee | 1.15B |
| Profits Per Employee | 334.57M |
| Employee Count | 4,770 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0.84 |
Taxes
In the past 12 months, KRX:207940 has paid 453.42 billion in taxes.
| Income Tax | 453.42B |
| Effective Tax Rate | 22.13% |
Stock Price Statistics
The stock price has increased by +11.06% in the last 52 weeks. The beta is 0.16, so KRX:207940's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +11.06% |
| 50-Day Moving Average | 1,636.00 |
| 200-Day Moving Average | 1,626.00 |
| Relative Strength Index (RSI) | 45.47 |
| Average Volume (20 Days) | 96,761 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:207940 had revenue of KRW 5.50 trillion and earned 1.60 trillion in profits. Earnings per share was 34,474.63.
| Revenue | 5.50T |
| Gross Profit | 3.08T |
| Operating Income | 2.02T |
| Pretax Income | 2.05T |
| Net Income | 1.60T |
| EBITDA | 2.69T |
| EBIT | 2.02T |
| Earnings Per Share (EPS) | 34,474.63 |
Balance Sheet
The company has 1.96 trillion in cash and 1.22 trillion in debt, giving a net cash position of 738.43 billion or 15,951.93 per share.
| Cash & Cash Equivalents | 1.96T |
| Total Debt | 1.22T |
| Net Cash | 738.43B |
| Net Cash Per Share | 15,951.93 |
| Equity (Book Value) | 12.18T |
| Book Value Per Share | 263,105.81 |
| Working Capital | 2.59T |
Cash Flow
In the last 12 months, operating cash flow was 2.22 trillion and capital expenditures -1,423.66 billion, giving a free cash flow of 791.56 billion.
| Operating Cash Flow | 2.22T |
| Capital Expenditures | -1,423.66B |
| Free Cash Flow | 791.56B |
| FCF Per Share | 17,099.61 |
Margins
Gross margin is 55.91%, with operating and profit margins of 36.64% and 28.99%.
| Gross Margin | 55.91% |
| Operating Margin | 36.64% |
| Pretax Margin | 37.23% |
| Profit Margin | 28.99% |
| EBITDA Margin | 48.83% |
| EBIT Margin | 36.64% |
| FCF Margin | 14.38% |
Dividends & Yields
KRX:207940 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 2.10% |
| FCF Yield | 1.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 30, 2025. It was a reverse split with a ratio of 0.6503913.
| Last Split Date | Oct 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.6503913 |
Scores
KRX:207940 has an Altman Z-Score of 8.48 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.48 |
| Piotroski F-Score | 7 |